Patients with advanced prostate cancer need more treatment options. One of the most important things we can do is help move promising science out of the lab and into the clinic.
That’s why I’m excited to share that @EMILosAngeles has entered into an exclusive license agreement with UniQuest to advance QED-203, a potential new treatment for metastatic castration-resistant prostate cancer (mCRPC).
Our team will leverage AI, preclinical research, and clinical expertise to help accelerate development and better understand its potential for patients.
There is still much work ahead, but this is an important step forward. I’m grateful to our partners at UniQuest and look forward to seeing where this collaboration leads.
Learn more: lnkd.in/gt35en6e
#ProstateCancer #mCRPC #CancerResearch #PatientsFirst #EllisonMedicalInstitute #UniQuest
That’s why I’m excited to share that @EMILosAngeles has entered into an exclusive license agreement with UniQuest to advance QED-203, a potential new treatment for metastatic castration-resistant prostate cancer (mCRPC).
Our team will leverage AI, preclinical research, and clinical expertise to help accelerate development and better understand its potential for patients.
There is still much work ahead, but this is an important step forward. I’m grateful to our partners at UniQuest and look forward to seeing where this collaboration leads.
Learn more: lnkd.in/gt35en6e
#ProstateCancer #mCRPC #CancerResearch #PatientsFirst #EllisonMedicalInstitute #UniQuest